Compare Barrick Gold Corp (B) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Barrick Gold Corp trades at $36.2 (market cap $60.50B), while State Street SPDR S&P Biotech ETF trades at $155.2. The key difference: Barrick Gold Corp pays a 1.92% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Barrick Gold Corp nearer its low. Which is the better fit depends on your goals.
| B | XBI | |
|---|---|---|
Market Cap | $60.50B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $52.97 | $164.28 |
52-Week Low | $20.73 | $85.16 |
Enterprise Value | $58.09B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $35.94, down 2.02% today, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and three consecutive quarterly EPS beats. Recent cash flow trends improved significantly, with 2025 net cash flow turning positive at $2.63 billion. The company announced a $0.18 dividend payable in June 2026.
The outlook remains positive given low valuation multiples, robust profitability, and analyst consensus of $52.67 price target. Key risks include gold price volatility and execution of growth projects. With 68% analyst buy ratings and no sell recommendations, Wall Street sentiment supports long-term upside potential despite near-term technical weakness.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
